Amid growing health crises and increasing global competition in pharmaceuticals, a novel FDA initiative aims to fast-track drug reviews by slashing approval times for essential medicines. Can this new approach significantly impact domestic drug manufacturing, or does it introduce unprecedented
The 2025 ASCO Annual Meeting brought groundbreaking advances and transformative developments to the oncology sphere. The event has long been a cornerstone for introducing innovative treatment paradigms and groundbreaking research in cancer therapy. This year, the conference sustained this trend by
What if the secret to faster and more effective cancer treatments isn't found in conventional laboratories but within the algorithms of artificial intelligence instead? Drug development has long been a drawn-out process, often taking over a decade to bring a new medication from concept to market.
With over ten million people worldwide battling Parkinson's disease, the quest for a treatment that not only controls symptoms but also halts the progression of this neurological disorder is of immense importance. Roche's recent advancement of prasinezumab, developed with Prothena, into Phase 3
In the swiftly changing world of biopharmaceuticals, the role of artificial intelligence (AI) is rapidly expanding, driving interest and speculation about its potential transformative effects on the industry. This landscape isn't just challenged by scientific demands but also by economic pressures,
In a major breakthrough in the field of drug development, revolutionary nanotechnology known as Facilitated Self-Assembling Technology (FAST) has been unveiled, promising to drastically transform drug solubility. Spearheaded by Stephen Hsu, PhD, a professor at the Dental College of Georgia, FAST
